IperionX Limited (IPX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q2 FY2026, filed Mar 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IPX SEC filings page.
This page shows IperionX Limited (IPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains in a development-and-financing phase: it has no reported revenue, while external funding supports rising losses and investment.
In FY2025, the net loss reached$35.3M , but operating cash flow was-$21.8M ; the smaller cash shortfall suggests noncash charges or working-capital movements softened the accounting loss, not that operations funded themselves. Capital spending then pushed free cash flow to-$38.8M , while financing provided$68.0M , linking asset expansion to continued external funding.
Total assets expanded from
The FY2025 net loss was
Financial Health Signals
IperionX Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
IperionX Limited passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
IperionX Limited reported a net loss of $35.3M while operations used $21.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2026.
Cash & Balance Sheet
IperionX Limited held $65.8M in cash against $4.5M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
IPX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
IPX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q4'256-K | Q2'2510-Q | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $129.2M+11.5% | $105.0M+89.5% | $115.8M+240.2% | $55.4M+143.1% | $34.0M+89.2% | $22.8M+130.1% | $18.0M | $9.9M+254.9% |
| Current Assets | $69.6M-11.7% | $58.9M+41.7% | $78.8M+234.3% | $41.5M+225.7% | $23.6M+100.1% | $12.8M+118.4% | $11.8M | $5.8M+234.2% |
| Cash & Equivalents | $65.8M-14.7% | $54.8M+65.3% | $77.1M+345.0% | $33.2M+177.7% | $17.3M+51.5% | $11.9M+110.5% | $11.4M | $5.7M+234.1% |
| Inventory | $426K | $0-100.0% | $0 | $17K | N/A | $0 | N/A | N/A |
| Accounts Receivable | $1.2M+18.1% | $823K-64.2% | $977K-63.9% | $2.3M+907.9% | $2.7M+3101.8% | $228K+913.3% | $84K | $23K+6510.0% |
| Total Liabilities | $21.0M+103.7% | $12.6M+207.4% | $10.3M+166.0% | $4.1M+82.8% | $3.9M+47.6% | $2.2M-10.0% | $2.6M | $2.5M+141.3% |
| Current Liabilities | $17.3M+158.7% | $8.4M+176.2% | $6.7M+154.1% | $3.1M+85.2% | $2.6M+43.3% | $1.6M-20.8% | $1.8M | $2.1M+226.5% |
| Non-Current Liabilities | $3.7M+2.0% | $4.2M+298.4% | $3.6M+191.1% | $1.0M+76.3% | $1.2M+57.4% | $593K+45.0% | $789K | $409K+3.6% |
| Long-Term Debt | $4.5M+23.9% | $3.9M+283.3% | $3.6M+195.0% | $1.0M+80.8% | $1.2M+60.4% | $568K+50.2% | $761K | $378K-4.2% |
| Total Equity | $108.2M+2.5% | $92.4M+80.1% | $105.5M+249.8% | $51.3M+149.7% | $30.2M+96.3% | $20.6M+177.1% | $15.4M | $7.4M+321.5% |
| Retained Earnings | -$144.0M-59.8% | -$109.2M-47.8% | -$90.1M-43.7% | -$73.9M-41.5% | -$62.7M-44.1% | -$52.2M-50.2% | -$43.5M | -$34.8M-162.7% |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
IPX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
IPX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| IperionX Limited IPX | FY2025 | N/A | -$35.3M | N/A | $506.4M | — |
| Ferroglobe PLC GSM | FY2025 | $1.3B | -$177.1M | -13.3% | $782.9M | 30/100 |
| Compass Minerals International, Inc. CMP | FY2025 | $1.2B | -$79.8M | -6.4% | $974.8M | 31/100 |
| Lithium Americas Corp. LAC | FY2025 | N/A | -$86.3M | N/A | $798.7M | — |
| Sigma Lithium Corporation SGML | FY2025 | $110.0M | -$50.2M | -45.6% | $979.3M | 14/100 |
Where IperionX Limited Ranks
Frequently Asked Questions
Is IperionX Limited profitable?
No, IperionX Limited (IPX) reported a net income of -$35.3M in fiscal year 2025.
How much debt does IperionX Limited have?
As of fiscal year 2025, IperionX Limited (IPX) had $54.8M in cash and equivalents against $3.9M in long-term debt.
What is IperionX Limited's return on equity (ROE)?
IperionX Limited (IPX) has a return on equity of -38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is IperionX Limited's free cash flow?
IperionX Limited (IPX) recorded an outflow of $38.8M in free cash flow during fiscal year 2025. This represents a -64.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is IperionX Limited's operating cash flow?
IperionX Limited (IPX) recorded an outflow of $21.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are IperionX Limited's total assets?
IperionX Limited (IPX) had $105.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are IperionX Limited's capital expenditures?
IperionX Limited (IPX) invested $17.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is IperionX Limited's current ratio?
IperionX Limited (IPX) had a current ratio of 6.99 as of fiscal year 2025, which is generally considered healthy.
What is IperionX Limited's debt-to-equity ratio?
IperionX Limited (IPX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is IperionX Limited's return on assets (ROA)?
IperionX Limited (IPX) had a return on assets of -33.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is IperionX Limited's P/E ratio?
IperionX Limited (IPX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $506.4M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is IperionX Limited's price-to-sales ratio?
IperionX Limited (IPX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $506.4M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is IperionX Limited's Piotroski F-Score?
IperionX Limited (IPX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are IperionX Limited's earnings high quality?
IperionX Limited (IPX) reported a net loss of $35.3M while operations used $21.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.